Aevi Genomic Medicine Reports Second Quarter 2017 Financial Results

Thursday, August 10, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share data)

Six months endedJune 30,

Three months endedJune 30,

2017

2016

2017

2016

Unaudited

Unaudited

Research and development expenses

$      13,614

$     15,692

$        5,667

$       8,741

General and administrative expenses

5,357

7,136

2,369

2,945

Operating loss

(18,971)

(22,828)

(8,036)

(11,686)

Financial income / (expense)

21

(20)

3

(18)

Loss before taxes on income

(18,950)

(22,848)

(8,033)

(11,704)

Taxes on income

-

3

-

3

Net loss

$     (18,950)

$    (22,851)

$       (8,033)

$    (11,707)

Basic and diluted loss per share

$         (0.51)

$        (0.69)

$         (0.22)

$        (0.35)

Weighted average number of common stock used incomputing basic loss per share

37,109,157

33,211,665

37,110,043

33,469,789



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook